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patients who need antifungal prophylaxis. METHODS: All claims data of patients 
who received HSCT between April 2010 and September 2013 were extracted from 
the database developed by MinaCare Co., Ltd. The database contains health check-
up and claims data obtained from approximately 2.1 million members of employ-
ment-based health insurance groups and their dependents. We defined prophylactic 
use of antifungal medication as prescription of antifungal drugs for more than 14 
consecutive days concomitantly with new quinolones, SMX/TMP and/or antivirus 
drugs. RESULTS: We identified 87 patients who received HSCT in the database 
altogether, of which 50 patients were considered to have received HSCT during 
the period examined. Among this population, 33 patients received the autologous 
peripheral blood stem cell transplantation and 14 patients received the cord blood 
stem cell transplantation (CBT). The major primary diseases were malignant lym-
phoma and multiple myeloma. Among the patients who received HSCT, 47 patients 
(94%) were prescribed with at least one antifungal, whereas those receiving CBT 
or those experienced graft versus host disease (GVHD) after transplantation had 
a tendency to be prescribed antimold drugs such as Micafungin and Voriconazole. 
In addition, 35 patients (70%) were prescribed antifungals as prophylaxis, as our 
definition above. CONCLUSIONS: This is the first investigation to demonstrate the 
percentage of HSCT recipients prescribed with antifungals, and that patients who 
received CBT or experienced GVHD had greater tendency to be prescribed anti-
mold agents. In order to assess the risk factors of invasive fungal infection in HSCT 
patients, further investigation is needed.
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OBJECTIVES: Although the compounds in marijuana increase appetite, empirical 
studies have estimated that marijuana users have lower BMI and rates of obe-
sity than non-users. Failure to account for differences in behaviors and attitudes 
increases the potential for confounding, since the decision to engage in marijuana 
use is tied to such attributes. This study investigated how estimates of the effect of 
marijuana use on BMI are altered by such considerations. METHODS: Participants in 
Wave IV of the National Longitudinal Study of Adolescent Health (Add Health) were 
interviewed between 2008 and 2009 (age 24-32). Multivariate regressions estimated 
the relationship between marijuana use and BMI (kg/m2). Regressions were then 
stratified by behavioral variables, including age of onset of marijuana use, concur-
rent alcohol use, self-assessed weight status, risk-propensity, and gender. RESULTS: 
Consistent with other empirical studies, marijuana use is associated with lower BMI 
in the core model (P= 0.015). However, results change when models are stratified 
by behavioral variables. The negative association between marijuana use and BMI 
persists in individuals who drink more than once a week (P< 0.05); however, in non-
drinkers (who have tried alcohol), the magnitude and direction of the effect changes 
drastically (-0.996, p= 0.015 vs. 7.96, p= 0.007). Users who initiated use at 17 or older 
do not have lower BMI (P= 0.937). In individuals who identified as satisfactory weight 
or overweight, there is no association (P= 0.313 and P= 0.748, respectively, vs. P = 
0.005 in underweight individuals). Estimates are negative and significant in self-
identified risk-takers (P= 0.037), but not in non-risk-takers (P= 0.549 and P= 0.401). 
Results are not significant in females (P= 0.976). CONCLUSIONS: The extent to which 
marijuana use influences BMI may depend on behavioral factors. Investigation is 
required to pinpoint behavioral attributes responsible for differences in BMI among 
marijuana users. The results have implications for assessing the role of marijuana 
in strategies to address obesity.
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OBJECTIVES: Phentermine and topiramate extended-release (PHEN/TPM ER) was 
approved by the US FDA in July 2012 for chronic weight management in combina-
tion with lifestyle modifications in adults with a body mass index (BMI) of ≥ 30 or 
≥ 27kg/m2and ≥ 1 weight-related comorbidity. This interim second analysis of a 
Phase 4 post-marketing study assessed the medical appropriateness of prescribed 
PHEN/TPM ER by examining the total number of PHEN/TPM ER users, their demo-
graphics, weight-related comorbidities, and concomitant medication use over 
18 months post-approval. METHODS: Data were collected from two databases 
between 17 September 2012 and 28 February 2014; the Qsymia Certified Pharmacy 
Network (QCPN) database collected age and gender information of all patients with 
≥ 1 recorded PHEN/TPM ER prescription; the Humedica Electronic Health Record 
(HEHR) database collected age, gender, race, BMI, weight-related comorbidities, 
and concomitant medication use. . Older patients (≥ 61 years) were evaluated for 
this subanalysis. RESULTS: There were 160,853 and 5253 patients in the QCPN and 
HEHR databases, respectively. Of these, 22,579 and 649 patients from the QCPN 
and HEHR databases, respectively were ≥ 61 years. Among older patients in the 
HEHR database, 73% were female, and mean BMI (kg/m2) was 36 (84% had BMI 
≥ 30 and 56% BMI ≥ 35) with < 2% having BMI ≤ 25. In the HEHR database, 71% had 
dyslipidemia, 69% had hypertension, and 37% had type 2 diabetes mellitus. In addi-
tion, 90% were prescribed antihypertensive medications, 46% antidiabetic medica-
tions, and 26% antidepressants (including SSRIs and SNRIs). CONCLUSIONS: These 
data demonstrate consistencies between patient demographics, weight-related 
comorbidities, and concomitant medication use among older patients prescribed 
PHEN/TPM ER, subjects randomized in the CONQUER clinical trial, and the labeled 
indication. Over 18 months of PHEN/TPM ER use, medically appropriate individu-
als, including older patients, are utilizing PHEN/TPM ER as intended for chronic 
weight management.
etanercept monotherapy were analyzed. RESULTS: 100 eligible AS patient charts 
were abstracted; 44 on adalimumab (male:77%, mean age:36.4yrs, average months 
on adalimumab:27.2, 86% on 1st-biologic, 11% on 2nd-biologic) and 38 on etaner-
cept (male:82%, mean age:42.8 yrs, average months on etanercept:55.5, 89% on 
1st-biologic, 11% on 2nd-biologic). Top-5 comorbidites (adalimumab vs. etaner-
cept) were obesity: 18% vs. 13%, depression/anxiety: 11% vs. 5%, dyslipidemia: 
9% vs. 0%, heart disease: 2% vs. 5%, and other gastrointestinal: 5% vs. 3%. Among 
patients with available data, latest lab measures documented were (adalimumab 
vs. etanercept): ESR: 22.2mm/h vs. 20.4mm/h, CRP: 2.6mg/dl vs. 2.5mg/dl, and rheu-
matoid factor-positive: 2% vs. 3%. Latest disease severity measures documented 
were (adalimumab vs. etanercept): Swollen Joint Counts: 0.5 vs. 0.6, Tender Joint 
Counts: 1.0 vs. 0.8, HAQ: 0.8 vs. 0.3. CONCLUSIONS: Among AS patients, patients 
on adalimumab monotherapy were younger and on adalimumab for fewer aver-
age months than patients on etanercept. Most (> 85%) were on their first biologic. 
The adalimumab group appeared to have a slightly higher disease burden and 
comorbidities. Factors influencing the observed patterns (including the choice 
of specific biologic for targeted patient profiles) may warrant further scrutiny to 
optimize therapeutic interventions and improve outcomes.
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OBJECTIVES: Bleeding still a concern in surgical procedures and it is strong corre-
lated with post-operative complications and increased hospital costs. Fibrin Sealant 
is wide used for this purpose, there are several commercially available fibrin seal-
ants to reduce bleeding, but only one with the lack of bovine derivatives, which 
may, decreases the risk of allergic reaction. The aim of this study was to systematic 
review the safety and efficacy of aprotinin free hemostatic sealant for bleeding con-
trol. METHODS: The electronic databases PubMed, EMBASE, The Cochrane Central 
Register of Controlled Trials, Wiley and OVID, were reviewed. The date limit was 
set to December 31th of 2014. Only English literature was considered. The stud-
ies included were RCTs in surgical patients, the intervention being, aprotinin free 
hemostatic sealant, and the comparison, conventional hemostatic techniques. The 
primary outcome was to evaluated blood loss and time to achieve hemostatic and 
the second outcome was risk of blooding transfusion. RESULTS: 266 records were 
identified in all databases described, 17 records met the inclusion criteria. 15 stud-
ies (1492 patients) investigated the effect of intervention in several types of surgery 
for blooding loss, 12 out 15 studies observed less blood loss and time to achieve 
hemostatic with aprotinin free hemostatic sealant compared with conventional 
techniques. Four studies addressed the secondary outcome of this review, with 
169 patients. Three of them investigated the use of aprotinin free hemostatic in 
knee arthroplasty, and only one trial (58 patients) showed significant risk reduction 
compared with control group (RR 0.31 95% IC 0.13-0.74). One study investigated the 
intervention in Hip arthroplasty and did not found any significance. No adverse 
events were reported. CONCLUSIONS: Aprotinin free hemostatic sealant is a safety 
approach for bleeding control, promoting less blood loss and time to achieve hemo-
static. Risk of Blood transfusion needs further investigation.
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OBJECTIVES: Heparin-induced thrombocytopenia (HIT) is a prothrombotic condition 
that requires immediate treatment, usually with direct thrombin inhibitors (DTIs). 
However, the treatment may cause major bleeding. Data comparing the effective-
ness and safety of DTIs in the treatment of HIT is limited. Therefore, we compared 
the effectiveness and safety of two commonly used DTIs, argatroban and bivalirudin, 
in patients with suspected HIT in a real-world setting. METHODS: The Clinical 
Database/Resource Manager data from the UHC were used to identify hospitalized 
patients with suspected HIT discharged between 2009 to 2012. Using propensity 
scores, up to three argatroban-treated patients were matched to each bivalirudin-
treated patient. The rates of thrombosis, major bleeding, amputation and mortality 
were compared using hazard ratios (HRs) from Cox proportional hazard regression 
models. RESULTS: Of the 2,408 matched patients, 709 (29.4%) received bivalirudin 
and 1,699 (70.6%) received argatroban. Compared to bivalirudin, argatroban exhib-
ited a less harmful effect for major bleeding based on blood transfusion (6.1% vs. 
11.4%; P< 0.05). The result did not change when major bleeding was defined as blood 
transfusion with diagnostic codes. The risk of thrombosis (7.7% vs. 9.5%; P= 0.14), 
amputation (2.1% vs. 2.0%; P= 0.82) and mortality (24.2% vs. 25.5%; P= 0.49) were 
similar in argatroban-and bivalirudin-treated patients. CONCLUSIONS: Among 
patients with suspected HIT, the use of argatroban compared to bivalirudin was 
associated with a decreased risk of major bleeding but was similar for thrombosis, 
amputation and mortality risk.
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OBJECTIVES: In this study, the actual clinical use of antifungal drugs in patients 
who received hematopoietic stem cell transplantation (HSCT) was investigated 
using a Japanese healthcare database. We also aim to identify characteristics of 
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OBJECTIVES: This study aimed to determine the budget impact of adding turocto-
cog alfa to a U.S. health plan insurer’s formulary for the treatment of hemophilia 
A. METHODS: A budget impact model was developed to evaluate factor replacement 
therapy costs, for patients with hemophilia A (without inhibitors), from the perspec-
tive of a US managed care plan. Key model inputs included benefit plan characteris-
tics (i.e. number of members and time frame of the model), patient characteristics 
(i.e. number of pediatric and adult patients; mean weight), treatment characteristics 
(i.e. prophylaxis, on-demand, or perioperative treatment), and disease outcomes 
(i.e. annual bleed rate, severity level of bleeding episode, bleed control, and major 
surgery). The model compared treatment with turoctocog alfa versus marketed 
recombinant and plasma-derived FVIII alternatives. For children and adults, base 
case weight-based dosage and frequency for prophylaxis was assumed to follow 
the Malmö Protocol, whereas on-demand and perioperative dosages were based on 
respective product package inserts. Market share was indexed at Year 1. All costs 
were based on estimated WAC drug costs (US dollars), and product information 
current as of January 15, 2015. RESULTS: For a hypothetical managed care plan 
with 1,000,000 members, the estimated number of hemophilia A patients was 39, 
based on US prevalence data. Assuming proportional adoption of turoctocog alfa 
from all branded rFVIII and plasma-derived FVIII, total annual treatment costs were 
$10,133,595 without turoctocog alfa and $10,138,671 with turoctocog alfa, resulting 
in a budget impact of $5,076 or $0.00042 per member per month (PMPM). Results 
were sensitive to prevalence of hemophilia A, drug cost, proportion of patients 
on prophylaxis, and proportion of major bleeding episodes for patients treated 
on-demand, based on one-way sensitivity analyses. CONCLUSIONS: Inclusion of 
turoctocog alfa on a formulary provides a budget neutral treatment option, having 
a negligible budget impact on the annual pharmacy budget.
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OBJECTIVES: To estimate the budget impact of adding rFVIIIFc to a managed care 
organization (MCO) formulary in the United States METHODS: A model was devel-
oped in Microsoft® Excel 2010 to evaluate the budget impact of including rFVIIIFc on 
formularies along with other recombinant FVIII (rFVIII) therapies over a 2-year time 
horizon. The model compared the drug-related costs of an MCO formulary contain-
ing conventional FVIII treatments with the costs of a formulary that also includes 
rFVIIIFc. The number of people with hemophilia A in the MCO was estimated using 
published prevalence data and was limited to adults with severe hemophilia A, 
free from FVIII inhibitors (neutralizing antibodies), receiving treatment with rFVIII 
therapy. It was assumed that 55% of patients receive prophylaxis therapy while 
the remaining 45% receive episodic therapy. Market share of rFVIIIFc was assumed 
to increase from 0% to 8.5% in year 1 and year 2. Medication costs were the only 
resource included in the budget impact model. The annual costs associated with 
factor replacement therapy were estimated by factor unit costs (acquisition cost) 
and by annual factor consumption. Annual factor consumption and bleeding rates 
were estimated using clinical trial and real world data. RESULTS: The estimated 
budget impact of adding rFVIIIFc to the formulary was associated with a budget 
increase of 1.4%/year for a private payer population of 1,000,000 plan members, with 
an estimated 21 members receiving treatment for hemophilia A. The overall impact 
to the budget was estimated to be $121,176 per year which corresponds to $0.01 per 
member per month, largely due to patients switching from episodic to prophylaxis 
therapy. Switching to rFVIIIFc therapy was projected to reduce the annual bleed rate 
by approximately 3.1 bleeds/patient/year, with an incremental cost of $1,880 per 
bleed avoided. CONCLUSIONS: Introduction of rFVIIIFc into MCO formularies may 
be associated with minimal budget impact.
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OBJECTIVES: Growing emphasis on cost containment in healthcare means that hos-
pitals must develop strategies to minimize adverse clinical outcomes while increas-
ing cost efficiency. A propensity-matched retrospective analysis of SIRS patients 
from a large US electronic health record (EHR) database identified significantly 
reduced odds of serious complications, when IV fluid therapy was predominantly 
with BAL versus 0.9% saline.[1]This analysis evaluates the economic implication 
of increasing usage of BAL for IV fluid therapy in SIRS patients from a US hospital 
perspective. Impact of Intravenous Fluid Composition on Outcomes in Patients with 
the Systemic Inflammatory Response Syndrome Andrew D. Shaw; Carol R. Schermer, 
Dileep N. Lobo, Sibyl H. Munson, Victor Khangulov, David Hayashida, and John A. 
Kellum: submitted for publication. METHODS: A budget impact model (BIM) was 
developed to assess the impact of increased usage of BAL in SIRS patients. Model 
parameters combined clinical inputs derived from the retrospective EHR analysis 
with fluid costs and complication-associated costs obtained from published reports 
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OBJECTIVES: The current study examined chronic pain prevalence in the U.S. 
Veterans Health Administration (VHA) population. METHODS: The study sample 
was based on the VHA Medical SAS Datasets from fiscal year 2008 through 2012. All 
patients diagnosed with chronic pain throughout the study period were identified 
using International Classification of Diseases, 9th Revision, Clinical Modification 
diagnosis codes 338.2 and 338.4. The variation in the prevalence of chronic pain 
was assessed and categorized according to the pain scale. Pain score was deter-
mined using a scale ranging from 0 to 10 as reported by patients using the follow-
ing categories: 1 to 4: mild, 5 to 6: moderate and ≥ 7: severe pain. To identify prior 
prevalence cases, we restricted continuous enrollment throughout that fiscal year 
and at least 2 years prior. RESULTS: In 2008, patients aged 45-64 had the highest 
percentage of patients with mild (56.4 %), moderate (60.7%) and severe (65.4%) 
pain. This trend was found for all study years. In 2008, white patients had the 
highest prevalence of mild (64.29%), moderate (62.07%) and severe (59.06%) pain. 
Similarly, in 2008, patients who resided in the South U.S. region had the highest 
prevalence of mild (32.89%), moderate (33.68%) and severe (36.39%) pain compared 
to other regions. This trend continued through all study years. Utah had the high-
est prevalence of chronic pain in 2008 (4.9%) and 2012 (24.0%). CONCLUSIONS: 
Among VHA beneficiaries with chronic pain, patients who were age 45-64 years 
had the highest prevalence of chronic pain. Also, white patients and those 
who resided in the South U.S. region had the highest prevalence of chronic 
pain.
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OBJECTIVES: An estimated 100 million adult Americans suffer from chronic 
pain. Prescribing opioids remains a primary treatment option for physicians. 
Hydrocodone/acetaminophen (HC/APAP) is the most commonly prescribed opioid 
in the US. However, the FDA recently rescheduled HC/APAP from Schedule III to II, 
due to negative outcomes, including its association with emergency department 
(ED) visits. The objective of this study was to estimate the impact of HC/APAP use 
in Texas on ED visits, based on the prevalence of HC/APAP prescriptions within the 
state. METHODS: A retrospective cohort design used data from the Drug Abuse 
Warning Network (DAWN) on ED visits associated with HC/APAP. Additionally, data 
from the Texas prescription drug monitoring program (PDMP) with patient level 
information for all Schedule II to V drugs dispensed within the state for a 12 month 
period was used to assess the prevalence of patients taking HC/APAP. This analysis 
yielded estimates of potential ED visits related to HC/APAP within Texas. RESULTS: 
National estimates from DAWN reveal that ED visits related to HC/APAP increased 
from 23.6 per 100,000 population in 2004 to 50.2 per 100,000 population in 2011. Data 
from the Texas PDMP contained 39,904,964 distinct prescriptions for all Schedule 
II to V controlled substances for the period from June 2013 to May 2014 within the 
state of Texas. CONCLUSIONS: The use of HC/APAP requires more active moni-
toring in order to reduce the number of ED visits associated with its use. Future 
studies should investigate whether rescheduling HC/APAP leads to reduction of 
related ED visits.
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OBJECTIVES: This study examined mortality risk among patients with psoriasis 
in the United States. METHODS: MarketScan databases were linked to the Social 
Security Administration death file to select adults with ≥ 1 inpatient or ≥ 2 outpa-
tient diagnoses of psoriasis (ICD-9-CM 696.1x) during the study period (1/1/2006 to 
6/30/2014). The first psoriasis diagnosis was the index date. Patients had 6 months 
of pre index continuous enrollment and were followed until the earliest of death or 
end of the study period. Comorbidities during the pre-index period were examined. 
Mortality incidence was calculated for psoriasis patients by comorbidities and age 
group. A Cox proportional hazards model was used to identify predictors of mortal-
ity. RESULTS: The sample comprised 102,573 psoriasis patients with mean age of 
52.7 years (yrs). Patients were followed for an average of 4.9 yrs and 3.4% died dur-
ing the study period. The mean age at death was 75.5 yrs. The mortality rate was 7.0 
per 1,000 person-years (PY) and increased with age (0.8 per 1,000 PY in patients aged 
18-24 yrs versus 45.5 per 1,000 PY in patients ≥ 75 yrs). The mortality rate was sig-
nificantly higher for psoriasis patients with (versus without) diabetes (17.5 vs. 5.7), 
hypertension (12.6 vs. 4.8), coronary heart disease (24.9 vs. 5.4), cerebrovascular 
disease (31.9 vs. 6.2), and peripheral vascular disease (36.8 vs. 6.1) (all p< 0.05). 
Multivariate analysis suggested that older age, female gender, higher Charlson 
Comorbidity Index (CCI) score, and presence of comorbidities (diabetes, coro-
nary heart disease, cerebrovascular disease, peripheral vascular disease, and 
malignancy) were associated with increased risk of mortality amongst pso-
riasis patients (all p< 0.001). CONCLUSIONS: Among patients with psoriasis, 
the rate of mortality was 7.0 per 1,000 person-years. Diabetes, cardiovascu-
lar diseases, malignancy, female gender, older age, and increased CCI scores 
were associated with an elevated risk of mortality in this cohort of psoriasis 
patients.
